BioCardia, Inc.

BCDA

NASDAQ

Healthcare

Biotechnology

Sunnyvale, CA, US17 employeesbiocardia.com

$1.19

+0.03(2.59%)

Mkt Cap $7M

$1.09

$3.14

52-Week Range

At a Glance

AI-generated

8-K

BioCardia, Inc. announced submission of CardiAMP HF clinical study data to the FDA and requested a meeting this quarter under its Breakthrough Therapy designation to discuss accelerated approval for the CardiAMP® System in ischemic chronic heart failure with reduced ejection fraction.

$7M

Market Cap

—

Revenue

-$8M

Net Income

Employees17

Fundamentals

How The Business Makes Money

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Industry Biotechnology

Activity

What Changed Recently

Regulation FD

Apr 1, 2026

, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

Regulation FD

Mar 2, 2026

, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

Other Event

Feb 9, 2026

, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

Other Event

Feb 2, 2026

, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,

Peer Companies

Company	Price	Change	Market Cap	P/E
PHIOPhio Pharmaceuticals Corp...	$1.27	-1.92%	$15M	-1.7
KPRXKiora Pharmaceuticals, In...	$1.96	+0.51%	$8M	-1.0
APVOAptevo Therapeutics Inc.	$4.13	-0.97%	$7M	-0.0
INABIN8bio, Inc.	$1.46	+3.93%	$7M	-0.4
ACXPAcurx Pharmaceuticals, In...	$3.72	-4.37%	$6M	-0.9
CELZCreative Medical Technolo...	$2.05	+3.02%	$5M	-0.7
APREAprea Therapeutics, Inc.	$0.71	+0.34%	$5M	-0.4
ALZNAlzamend Neuro, Inc.	$0.99	-2.91%	$3M	-1.0

Analyst View

Company Profile

CIK0000925741

ISINUS09060U6064

CUSIP09060U507

Phone650 226 0120

Address320 Soquel Way, Sunnyvale, CA, 94085, US

SEC EDGAR